Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A thorough QT study of Roluperidone (MIN-101)

Trial Profile

A thorough QT study of Roluperidone (MIN-101)

Phase of Trial: Phase I

Latest Information Update: 07 Dec 2018

At a glance

  • Drugs Roluperidone (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Registrational
  • Most Recent Events

    • 07 Dec 2018 New trial record
    • 19 Nov 2018 According to a Minerva Neurosciences media release, this study has been planned as part of the New Drug Application (NDA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top